JP6865826B2 - インターロイキン１７ａを標的とする抗体、その製造方法及び応用 - Google Patents

インターロイキン１７ａを標的とする抗体、その製造方法及び応用 Download PDF

Info

Publication number
JP6865826B2
JP6865826B2 JP2019528444A JP2019528444A JP6865826B2 JP 6865826 B2 JP6865826 B2 JP 6865826B2 JP 2019528444 A JP2019528444 A JP 2019528444A JP 2019528444 A JP2019528444 A JP 2019528444A JP 6865826 B2 JP6865826 B2 JP 6865826B2
Authority
JP
Japan
Prior art keywords
antibody
seq
chain variable
variable region
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019528444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537617A5 (https=
JP2019537617A (ja
Inventor
向▲陽▼ 朱
向▲陽▼ 朱
明清 蔡
明清 蔡
▲海▼佳 于
▲海▼佳 于
慧峰 ▲賈▼
慧峰 ▲賈▼
玲 ▲兪▼
玲 ▲兪▼
Original Assignee
▲華▼博生物医▲薬▼技▲術▼（上▲海▼）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ▲華▼博生物医▲薬▼技▲術▼（上▲海▼）有限公司 filed Critical ▲華▼博生物医▲薬▼技▲術▼（上▲海▼）有限公司
Publication of JP2019537617A publication Critical patent/JP2019537617A/ja
Publication of JP2019537617A5 publication Critical patent/JP2019537617A5/ja
Application granted granted Critical
Publication of JP6865826B2 publication Critical patent/JP6865826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019528444A 2017-07-21 2018-01-19 インターロイキン１７ａを標的とする抗体、その製造方法及び応用 Active JP6865826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710602383.3 2017-07-21
CN201710602383.3A CN108359011B (zh) 2017-07-21 2017-07-21 靶向于白介素17a的抗体、其制备方法和应用
PCT/CN2018/073458 WO2019015282A1 (zh) 2017-07-21 2018-01-19 靶向于白介素17a的抗体、其制备方法和应用

Publications (3)

Publication Number Publication Date
JP2019537617A JP2019537617A (ja) 2019-12-26
JP2019537617A5 JP2019537617A5 (https=) 2021-04-01
JP6865826B2 true JP6865826B2 (ja) 2021-04-28

Family

ID=63009922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528444A Active JP6865826B2 (ja) 2017-07-21 2018-01-19 インターロイキン１７ａを標的とする抗体、その製造方法及び応用

Country Status (5)

Country Link
US (1) US10981983B2 (https=)
EP (1) EP3656789A4 (https=)
JP (1) JP6865826B2 (https=)
CN (1) CN108359011B (https=)
WO (1) WO2019015282A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
CN113769082A (zh) * 2020-06-10 2021-12-10 上海君实生物医药科技股份有限公司 抗il-17a抗体药物组合物及其用途
CN112300285B (zh) * 2020-11-06 2022-08-02 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素17单克隆抗体含量的酶联免疫分析方法
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
CN114380906B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 一种抗il-17a的单域抗体及其用途
CN115819579B (zh) * 2022-11-10 2023-11-07 浙江大学 全人源抗白介素17A单链抗体No.34及应用
WO2024120518A1 (zh) 2022-12-09 2024-06-13 上海华奥泰生物药业股份有限公司 Il-17a抗体制剂及其用途
TW202444410A (zh) * 2023-01-19 2024-11-16 大陸商上海華奧泰生物藥業股份有限公司 一種治療系統性紅斑狼瘡的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
PT1981902E (pt) 2006-01-27 2015-11-02 Biogen Ma Inc Antagonistas dos recetores nogo
TWI541021B (zh) * 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
EP2493506B1 (en) 2009-10-30 2019-04-10 Janssen Biotech, Inc. Il-17a antagonists
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
LT2953969T (lt) 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
HUE052184T2 (hu) 2013-11-18 2021-12-28 Shanghai hengrui pharmaceutical co ltd IL-17A kötõanyag és felhasználásai
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
CN106336459B (zh) * 2015-07-13 2020-12-08 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用

Also Published As

Publication number Publication date
JP2019537617A (ja) 2019-12-26
EP3656789A4 (en) 2021-04-28
WO2019015282A1 (zh) 2019-01-24
US20200071394A1 (en) 2020-03-05
US10981983B2 (en) 2021-04-20
EP3656789A1 (en) 2020-05-27
CN108359011B (zh) 2019-06-25
CN108359011A (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
JP6865826B2 (ja) インターロイキン１７ａを標的とする抗体、その製造方法及び応用
KR102037016B1 (ko) 항 pd-l1 나노 항체 및 이의 응용
US11555077B2 (en) 4-1BB antibody and preparation method and use thereof
US12098195B2 (en) Anti-IL-23p19 antibody and use thereof in treating diseases
JP2021526022A (ja) 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用
CN107522783B (zh) 一种抗白介素17a的抗体、其制备方法和应用
EP4257605A1 (en) Anti-tslp nanobody and use thereof
WO2017215524A1 (zh) 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
TWI827980B (zh) 結合人il-33的抗體、其製備方法和用途
KR20230098606A (ko) 인터루킨 36r을 표적으로 하는 항체 및 이의 제조 방법과 용도
EP4660205A1 (en) Multiple antibodies against human il-36r and/or human il-1r3, and uses thereof
CN118063607A (zh) 抗犬il-31抗体及其用途
EP4289863A9 (en) Bispecific antibody targeting il-17a and il-36r and application thereof
CN110606892B (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
CA3229503A1 (en) Pharmaceutical composition containing fusion protein
CN117843776B (zh) 抗体分子、核酸、制药用途及炎性疾病治疗方法
HK40022398A (en) Antibody targeting interleukin 17a and preparation method and application thereof
HK1243095B (zh) 一种抗白介素17a 的抗体、其制备方法和应用
HK1243095A1 (en) An anti-il-17a antibody, the preparation method and application thereof
HK1243095A (en) An anti-il-17a antibody, the preparation method and application thereof
TW202334214A (zh) 抗il-17/vegf雙功能融合蛋白及其用途
KR20240017071A (ko) 항-masp-2 항체 및 이의 용도
CN111040033A (zh) 靶向肿瘤细胞的抗人角蛋白18的单克隆抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201116

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210406

R150 Certificate of patent or registration of utility model

Ref document number: 6865826

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250